Silexion Therapeutics Corp (NASDAQ:SLXN) shares, rose in value, with the stock price down by -5.20% to the previous day’s close as strong demand from buyers drove the stock to $0.70.
Actively observing the price movement in the recent trading, the stock is buoying the session at $0.74, falling within a range of $0.6851 and $0.758. The value of beta (5-year monthly) is -0.111. Referring to stock’s 52-week performance, its high was $122.02, and the low was $0.73. On the whole, SLXN has fluctuated by -70.95% over the past month.
With the market capitalization of Silexion Therapeutics Corp currently standing at about $2.81 million, investors are eagerly awaiting this quarter’s results, scheduled for in February.
The stock’s technical analysis shows that the price of SLXN currently trading nearly -60.15% and -69.64% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 24.06, while the 7-day volatility ratio is showing 20.64% which for the 30-day chart, stands at 16.83%. Furthermore, Silexion Therapeutics Corp (SLXN)’s beta value is -0.13, and its average true range (ATR) is 0.33.
A comparison of Silexion Therapeutics Corp (SLXN) with its peers suggests the former has fared considerably weaker in the market. SLXN showed an intraday change of -5.20% in today’s session so far, and over the past year, it shrunk by -99.23%%.
Data on historical trading for Silexion Therapeutics Corp (NASDAQ:SLXN) indicates that the trading volumes over the past 10 days have averaged 2.73 and over the past 3 months, they’ve averaged 1.22 million. According to company’s latest data on outstanding shares, there are 4.00 million shares outstanding.
Nearly 35.02% of Silexion Therapeutics Corp’s shares belong to company insiders and institutional investors own 3.25% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 35842.0 shares as on 2024-11-15, resulting in a short ratio of 0.23. According to the data, the short interest in Silexion Therapeutics Corp (SLXN) stood at 308.00 of shares outstanding as of 2024-11-15; the number of short shares registered in 2024-10-15 reached 9885.0. The stock has fallen by -65.02% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the SLXN stock heading into the next quarter.
